Empfohlen
Empfohlen
Weitere Àhnliche Inhalte
Was ist angesagt?
Was ist angesagt? (20)
Andere mochten auch
Andere mochten auch (20)
Ăhnlich wie Fatty Liver Disease - Kuwait
Ăhnlich wie Fatty Liver Disease - Kuwait (20)
Mehr von Neil Theise
Mehr von Neil Theise (13)
KĂŒrzlich hochgeladen
KĂŒrzlich hochgeladen (20)
Fatty Liver Disease - Kuwait
- 1. Fatty Liver Disease Neil Theise, MD Depts of Pathology and Medicine (Digestive Diseases) Beth Israel Medical Center â Albert Einstein College of Medicine New York City
- 2. Alcoholic And Non-alcoholic Fatty Liver Disease (NAFLD)
- 3. Alcoholic And Non-alcoholic Fatty Liver Disease (NAFLD) NOT NASH!
- 4. Non-alcoholic Fatty Liver Disease (NAFLD) Obesity Diabetes Mellitus Dyslipidemia syndromes Drug toxicities
- 5. Non-alcoholic Fatty Liver Disease (NAFLD) Obesity Diabetes Mellitus Dyslipidemia syndromes Metabolic Syndrome!!!
- 6. Â
- 7. Â
- 8. Â
- 9. Obesity Trends* Among U.S. Adults BRFSS, 1985 No Data <10% 10%â14%
- 10. Obesity Trends* Among U.S. Adults BRFSS, 1986 No Data <10% 10%â14%
- 11. Obesity Trends* Among U.S. Adults BRFSS, 1987 No Data <10% 10%â14%
- 12. Obesity Trends* Among U.S. Adults BRFSS, 1988 No Data <10% 10%â14% No Data <10% 10%â14%
- 13. Obesity Trends* Among U.S. Adults BRFSS, 1989 No Data <10% 10%â14%
- 14. Obesity Trends* Among U.S. Adults BRFSS, 1990 No Data <10% 10%â14%
- 15. Obesity Trends* Among U.S. Adults BRFSS, 1991 No Data <10% 10%â14% 15%â19%
- 16. Obesity Trends* Among U.S. Adults BRFSS, 1992 No Data <10% 10%â14% 15%â19%
- 17. Obesity Trends* Among U.S. Adults BRFSS, 1993 No Data <10% 10%â14% 15%â19%
- 18. Obesity Trends* Among U.S. Adults BRFSS, 1994 No Data <10% 10%â14% 15%â19%
- 19. Obesity Trends* Among U.S. Adults BRFSS, 1995 No Data <10% 10%â14% 15%â19%
- 20. Obesity Trends* Among U.S. Adults BRFSS, 1996 No Data <10% 10%â14% 15%â19%
- 21. Obesity Trends* Among U.S. Adults BRFSS, 1997 No Data <10% 10%â14% 15%â19% â„20%
- 22. Obesity Trends* Among U.S. Adults BRFSS, 1998 No Data <10% 10%â14% 15%â19% â„20%
- 23. Obesity Trends* Among U.S. Adults BRFSS, 1999 No Data <10% 10%â14% 15%â19% â„20%
- 24. Obesity Trends* Among U.S. Adults BRFSS, 2000 No Data <10% 10%â14% 15%â19% â„20%
- 25. Obesity Trends* Among U.S. Adults BRFSS, 2001 No Data <10% 10%â14% 15%â19% 20%â24% â„25%
- 26. Obesity Trends* Among U.S. Adults BRFSS, 2002 No Data <10% 10%â14% 15%â19% 20%â24% â„25%
- 27. Obesity Trends* Among U.S. Adults BRFSS, 2003 No Data <10% 10%â14% 15%â19% 20%â24% â„25%
- 28. Obesity Trends* Among U.S. Adults BRFSS, 2004 No Data <10% 10%â14% 15%â19% 20%â24% â„25%
- 29. Obesity Trends* Among U.S. Adults BRFSS, 2005 No Data <10% 10%â14% 15%â19% 20%â24% 25%â29% â„30%
- 30. Obesity Trends* Among U.S. Adults BRFSS, 2006 No Data <10% 10%â14% 15%â19% 20%â24% 25%â29% â„30%
- 31. Obesity Trends* Among U.S. Adults BRFSS, 2007 No Data <10% 10%â14% 15%â19% 20%â24% 25%â29% â„30%
- 32. Obesity Trends* Among U.S. Adults BRFSS, 2008 No Data <10% 10%â14% 15%â19% 20%â24% 25%â29% â„30%
- 33. Â
- 34. Â
- 35. And now⊠⊠pathology!
- 36. Independent of etiology, 3 features to assess:
- 37. Independent of etiology, 3 features to assess: 1. Steatosis
- 43. Â
- 44. Â
- 53. Â
- 54. Â
- 56. Â
- 57. Â
- 59. Â
- 62. Â
- 64. 2. Steatohepatitis Portal inflammation�
- 65. Â
- 68. Â
- 70. Â
- 71. Â
- 72. Â
- 74. Â
- 75. Â
- 77. Active EtOH Use
- 80. Active EtOH Use > 6 months abstinence
- 81. Active EtOH Use > 6 months abstinence 4 years abstinence
- 82. Sample Diagnoses
- 83. LIVER: NEEDLE BIOPSY - STEATOSIS, MODERATE, WITH STEATOHEPATITIS AND STEATOFIBROSIS (CENTRAL-PORTAL SEPTA) c/w ALCOHOLIC LIVER DISEASE.
- 84. LIVER: NEEDLE BIOPSY - STEATOSIS, SEVERE, WITH STEATOHEPATITIS AND STEATOFIBROSIS (CENTRAL-PORTAL SEPTA) c/w ALCOHOLIC LIVER DISEASE.
- 85. LIVER: NEEDLE BIOPSY - STEATOSIS, MODERATE, INDICATIVE OF FATTY LIVER DISEASE, ? ALCOHOLIC VS. NON-ALCOHOLIC
- 86. LIVER: NEEDLE BIOPSY - STEATOSIS, MODERATE, WITH STEATOHEPATITIS COMPATIBLE WITH OBESITY RELATED FATTY LIVER DISEASE.
- 88. In childrenâŠ.
- 90. Microvesicular Steatosis 5ive Causes!
- 92. ?âs
Hinweis der Redaktion
- Table 7.1. Metabolic syndrome1</sup
- Fig. 7.29. The same flow chart as Fig. 7.28 with emphasis on the concepts developed largely in animal models that the lesions associated with steatohepatitis are explained by pathogenetic models.
- Fig. 7.28. A simplified flow chart of the cyclic pathogenic events that both lead to and result in steatosis and steatohepatitis.
- Fig. 7.9. Most of the ballooned hepatocytes in this field contain intracytoplasmic ropy material consistent with Malloryâs hyaline. Satellitosis can be seen. H&amp;E.
- Fig. 7.11. The frequency of megamitochondria in NAFLD and NASH has not been rigorously evaluated. This example shows round intracytoplasmic inclusions that are characteristic of megamitochondria. Needle-shaped inclusions may also be seen. H&amp;E (reproduced with permission from Kliener DE et al. Hepatology 2005; 41: 1313â1321 with permission).
- Fig. 7.5. Portal inflammation in NASH is common, but usually mild. H&amp;E.
- Fig. 7.7. On this higher power view, the distinct pericellular, perisinusoidal location of collagen deposition can be seen. Masson trichrome.
- Fig. 7.6. Collagen deposition can be appreciated in zone 3 in this low power photomicrograph. Masson trichrome.
- Fig. 7.18. Paediatric NAFLD. A low power photomicrograph of a paediatric liver biopsy shows diffuse steatosis with prominent portal tracts. The latter is due to inflammation and slightly increased fibrosis. There was no ballooning or zone 3 perisinusoidal fibrosis. H&amp;E. (Courtesy Dr Cynthia Behling)